SA-201

N/A

Report date: 2026/04/24 15:37:23

Base Information

Drug NameSA-201
Drug Alias NameSA-201 CAR-iPSC-NKSA-201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy > In vivo CAR-NK therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-NK therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLarge B Cell LymphomaLupus Erythematosus, SystemicLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Sian Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Sian Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLarge B Cell LymphomaLupus Erythematosus, SystemicLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A